(Q46598053)

23 December 2017

title

An analysis fo causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine (English)

1 reference

23 December 2017

1 reference

1 reference

R Morillo Verdugo

1

1 reference

23 December 2017

L Abdel-Kader Martín

2

1 reference

23 December 2017

E Márquez Saavedra

3

1 reference

23 December 2017

I Martínez Alonso

4

1 reference

23 December 2017

S Artacho Criado

5

1 reference

23 December 2017

C Almeida González

6

1 reference

23 December 2017

M Miguel Del Corral

7

1 reference

23 December 2017

publication date

1 May 2005

1 reference

23 December 2017

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

published in

1 reference

23 December 2017

volume

29

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

164-170

1 reference

23 December 2017

Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Heterosexual men and women with HIV test positive at a later stage of infection than homo- or bisexual men

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Factors predicting lack of adherence to highly active antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2805%2973658-8

7 January 2021

10.1016/S1130-6343(05)73658-8

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017